Please select the eligibility criteria that correspond to the clinical trial below.
Title: CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness
Brief Summary: The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine psychiatric care setting. Aripiprazole will be investigated in a descriptive manner.


Options:
A: Inclusion Criteria:

* Diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV)
* Patients currently treated with oral risperidone, olanzapine or a conventional neuroleptic monotherapy at doses not exceeding 6 mg risperdal, 20 mg olanzapine, or a conversion dose of 10 mg haloperidol for oral conventional agents
* Patients who are stable (judged clinically stable by the investigator and on a stable dose of medication for 4 weeks or longer) but not optimally treated (non-satisfactory treatment regarding symptoms or adverse events)

Exclusion Criteria:

* Diagnosis other than schizophrenia or schizoaffective disorder by DSM-IV Axis I criteria
* Patients being treated with antipsychotic agents other than oral risperidone, olanzapine or conventional oral neuroleptic agents
* Patients with known hypersensitivity to oral risperidone, quetiapine, aripiprazole, or who are known non-responders to oral risperidone, quetiapine, aripiprazole or to previous treatment with at least 2 antipsychotic agents
* Patients treated with mood stabilizers or antidepressants who are not on stable dose for at least 3 months before study initiation
* Pregnant or nursing females, or those lacking adequate contraception
B: Inclusion Criteria:

* Ages 18-65
* Schizophrenia or schizoaffective disorder
* Meets the Structured Clinical Interview for DSM-IV (SCID) criteria for an alcohol use disorder
* Alcohol use on at least 5 days during the 4 weeks prior to randomization
* Patient is medically stable to start either form of risperidone.

Exclusion Criteria:

* Current treatment with clozapine.
* Current treatment with injectable risperidone long-acting.
* Currently pregnant, planning to become pregnant, or unwilling to use an acceptable form of birth control.
* Change in medications (dose of current medication, discontinuation of medication, or new medication) in past 30 days.
* History of or current breast cancer.
* History of intolerance of or allergy to risperidone or risperidone long-acting.
* Currently residing in a residential program designed to treat substance use disorders.
* Current treatment with long-acting, injectable antipsychotic medication will require a review by the medication adjustment group before entering the client into the study.
* Past treatment with risperidone long-acting will require a review by the medication adjustment group before entering the client into the study.
* Treatment at baseline with a second antipsychotic medication will require a review by the medication adjustment group before entering the client into the study.
* Treatment at baseline with a psychotropic agent proposed to curtail substance use will require a review by the medication adjustment group before entering the client into the study.
* Patients who, in the opinion of the investigator, are judged unsuitable to participate in the study.
C: Inclusion Criteria:

* Meets diagnosis criteria for Bipolar I Disorder - Most Recent Episode Manic (Diagnostic and Statistical Manual of Mental Diseases, 4th edition, (DSM-IV))
* meets DSM-IV criteria for a current manic episode
* hospitalized voluntarily at study initiation
* history of at least one documented manic or mixed episode prior to study initiation
* total score of \>=20 on the Young Mania Rating Scale (YMRS) and total score of \<=20 on the Montgomery Asberg Depression Rating Scale (MADRS) at start of the study

Exclusion Criteria:

* Meets DSM-IV criteria for Schizoaffective Disorder or for rapid cycling
* borderline or antisocial personality disorder
* history of substance dependence (excluding nicotine and caffeine) within the 3 months prior to study initiation
* seizure disorder
* females who are pregnant or nursing, or those lacking adequate contraception.
D: Inclusion criteria:

1. English-speaking men and women (20-50 years old) of all ethnic origins
2. Outpatients with a current DSM-IV diagnosis of bipolar I with or without psychotic features or bipolar II disorder
3. Current cocaine or methamphetamine dependence
4. Currently experiencing hypomanic, manic, or mixed state episodes with a Young Mania Rating Scale23 (YMRS11) score of \> 9
5. Currently craving stimulants with a craving score of \> 20 on the 10-item, self-reported Stimulant Craving Questionnaire24 (SCQ10)
6. A high school diploma, GED, or Shipley IQ test score of \>85.

Exclusion criteria:

1. Inpatients or anyone with a high risk for suicide (i.e., active suicidal ideation with a proposed plan, history of any suicide attempt within the last 6 months)
2. DSM-IV diagnosis of substance-induced mood disorder
3. Pregnant or breast-feeding
4. History of special education, mental retardation, dementia
5. HIV/AIDS, reactive hepatitis, hepatic cirrhosis or any active liver disease, personal or familial history of diabetes, personal history of heart disease (i.e., congenital heart abnormalities, congestive heart failure, chronic atrial fibrillation, rheumatic heart disease, heart attack)
6. Central nervous system diseases (e.g., multiple sclerosis, severe head trauma, or seizures)
7. Contraindications or allergic reactions to study medications
8. Currently participating in any other research program
9. Urine positive for glucose or ketones
10. Currently receiving any antipsychotic medications or more than two psychotropic medications
11. Currently receiving benzodiazepines, sedatives or stimulants
12. Any other current substance dependence
13. Cataracts or glaucoma
14. EKG evidence of QT prolongation.

Answer: A